Legacy Trust Buys Shares of 12,666 Illumina, Inc. (NASDAQ:ILMN)

Legacy Trust purchased a new position in shares of Illumina, Inc. (NASDAQ:ILMN) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 12,666 shares of the life sciences company’s stock, valued at approximately $1,693,000.

Several other institutional investors and hedge funds have also recently modified their holdings of ILMN. Geode Capital Management LLC grew its stake in shares of Illumina by 1.8% in the 3rd quarter. Geode Capital Management LLC now owns 2,727,827 shares of the life sciences company’s stock valued at $354,933,000 after buying an additional 48,018 shares during the period. Primecap Management Co. CA lifted its holdings in Illumina by 3.6% in the third quarter. Primecap Management Co. CA now owns 2,516,359 shares of the life sciences company’s stock valued at $328,158,000 after acquiring an additional 87,599 shares during the last quarter. Janus Henderson Group PLC lifted its holdings in Illumina by 40.5% in the third quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company’s stock valued at $282,735,000 after acquiring an additional 625,245 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Illumina by 4.5% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,260,137 shares of the life sciences company’s stock worth $164,334,000 after acquiring an additional 54,319 shares during the period. Finally, Massachusetts Financial Services Co. MA increased its stake in Illumina by 148.6% during the third quarter. Massachusetts Financial Services Co. MA now owns 1,056,172 shares of the life sciences company’s stock worth $137,735,000 after acquiring an additional 631,294 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Stock Performance

Shares of NASDAQ:ILMN opened at $131.72 on Thursday. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94. Illumina, Inc. has a fifty-two week low of $100.08 and a fifty-two week high of $156.66. The firm’s 50 day moving average price is $139.05 and its 200 day moving average price is $135.07.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.26. The company had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.08 billion. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. Illumina’s revenue was down 3.5% compared to the same quarter last year. During the same period in the previous year, the company posted $0.33 EPS. Equities research analysts predict that Illumina, Inc. will post 4.13 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ILMN has been the topic of several recent analyst reports. HSBC raised Illumina from a “hold” rating to a “buy” rating and set a $180.00 price target on the stock in a research note on Thursday, October 17th. Hsbc Global Res raised shares of Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 target price for the company in a research note on Thursday, October 17th. Canaccord Genuity Group boosted their price target on shares of Illumina from $130.00 to $145.00 and gave the company a “hold” rating in a research note on Tuesday, November 5th. UBS Group increased their price objective on shares of Illumina from $133.00 to $145.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Finally, Citigroup downgraded shares of Illumina from a “buy” rating to a “neutral” rating and dropped their target price for the company from $190.00 to $165.00 in a report on Wednesday, December 11th. Eight research analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $165.63.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.